PI: Professor Indraneel Mittra

Lab Members

Selected Publications

  1. Mittra I. Circulating nucleic acids: a new class of physiological mobile genetic elements. F1000Research (In Press).

  2. Mittra I, Khare NK, Raghuram GV, Chaubal R, Khambatti F, Gupta D, Gaikwad A, Prasannan P, Singh A, Iyer A, Singh A, Upadhyay P, Nair NK, Mishra PK, Dutt A. 2015. Circulating nucleic acids damage DNA of healthy cells by integrating into their genomes. J Biosci. 40(1):91-111.

  3. Shastri SS, Mittra I, Mishra GA, Gupta S, Dikshit R, Singh S, Badwe RA. 2014. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst. 106(3):dju009. doi: 10.1093/jnci/dju009.

  4. Rekha MR, Pal K, Bala P, Shetty M, Mittra I, Bhuvaneshwar GS, Sharma CP. 2013. Pullulan-histone antibody nanoconjugates for the removal of chromatin fragments from systemic circulation. Biomaterials. 34(27):6328-38. doi:10.1016/j.biomaterials.2013.05.019.

  5. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. 2013. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 381(9869):805-16. Erratum in: Lancet. 2013; 381(9869):804.

  6. Badwe R, Hawaldar R, Parmar V, Nadkarni M, Shet T, Desai S, Gupta S, Jalali R, Vanmali V, Dikshit R, Mittra I. 2011. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J Clin Oncol. 29(21):2845-51. doi:10.1200 / JCO.2010.33.0738.

  7. Mittra I. 2009. Why is modern medicine stuck in a rut? Perspect Biol Med. 52(4):500-17. doi: 10.1353/pbm.0.0131.

  8. Mittra I, Mishra GA, Singh S, Aranke S, Notani P, Badwe R, Miller AB, Daniel EE, Gupta S, Uplap P, Thakur MH, Ramani S, Kerkar R, Ganesh B, Shastri SS. 2010. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer. 126(4):976-84. doi: 10.1002/ijc.24840.

  9. Mittra I. 1997. Clinical cancer trials in developing countries. Lancet. 349(9047):290.

  10. Baum M, Vaidya JS, Mittra I. 1997. Multicentricity and recurrence of breast cancer. Lancet. 349(9046):208.

  11. Bhattacharya D, Redkar A, Mittra I, Sutaria U, MacRae KD. 1997. Oestrogen increases S-phase fraction and oestrogen and progesterone receptors in human cervical cancer in vivo. Br J Cancer. 75(4):554-8.

  12. Chakravarty G, Redkar A, Mittra I. 1996. A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing. Br J Cancer. 74(8):1181-7.

  13. Vaidya JS, Vyas JJ, Chinoy RF, Merchant N, Sharma OP, Mittra I. 1996. Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer. 74(5):820-4.

  14. Childhood ALL Collaborative Group. 1996. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomised children. Lancet. 347(9018):1783-8.

  15. Mittra I. 1994. Breast screening: the case for physical examination without mammography. Lancet. 343(8893):342-4.

  16. Mittra I, MacRae KD. 1991. A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology? Eur J Cancer. 27(12):1574-83.

  17. Mittra I, Badwe RA, Desai PB, Yeole BB, Jussawalla DJ. 1989. Early detection of breast cancer in developing countries. Lancet. 1(8640):719-20.

  18. Mittra I. 1984. Somatomedins and proteolytic bioactivation of prolactin and growth hormone. Cell. 38(2):347-8.

  19. Mittra I. 1980. A novel "cleaved prolactin" in the rat pituitary: Part II. In vivo mammary mitogenic activity of its N-terminal 16K moiety. Biochem Biophys Res Commun. 95(4):1760-7.

  20. Mittra I. 1980. A novel "cleaved prolactin" in the rat pituitary: part I. Biosynthesis, characterization and regulatory control. Biochem Biophys Res Commun. 95(4):1750-9.

  21. Mittra I, Perrin J, Kumaoka S. 1976. Thyroid and other autoantibodies in British and Japanese women: an epidemiological study of breast cancer. Br Med J. 1(6004):257-9.

  22. Mittra I, Hayward JL, McNeilly AS. 1974. Hypothalamic-pituitary-prolactin axis in breast cancer. Lancet. 1(7863):889-91.

  23. Mittra I, Hayward JL. 1974. Hypothalamic-pituitary-thyroid axis in breast cancer. Lancet. 1(7863):885-9.

  24. Mittra I. 1974. Mammotropic effect of prolactin enhanced by thyroidectomy. Nature. 248(448):525-6.